Amino, a Germany-based manufacturer of pharmaceutical- and infusion-grade natural amino acids and similar active substances for a variety of applications, plans to double its production capacity with a new plant at its site in Frellstedt, Germany.

The company said the new facility, to cost around $35 million, will go on stream in 2021 and help meet growing demand from current customers as well as increasing supply to the worldwide pharmaceutical and nutritional market, with a specific focus on the Americas.

Amino specializes in amino acids for infusions and injections, active pharmaceutical ingredients for oral applications, pharmaceutical intermediates, pharmaceutical production in cell culture and medical nutrition and infant formula.

With the expansion, the company will add about 1,200 ty t of output capability across all product lines, covering the complete range of pharmaceutical grade amino acids for customers in Europe, Asia and the Americas.

Current growth is exhausting the company’s production resources, and it now needs to think bigger and beyond its European base, said Kai-Phillipp Thomas, vice president Sales & Marketing.

Thomas added that with the new capability, Amino will be able to supply new customers, particularly pharmaceutical companies in the US, while continuing to meet increasing demand from its existing customer base.

The company notes that it has passed US Food & Drug Administration (FDA) inspections and holds several US-Drug Master Files. 

All of Amino’s products are manufactured at Frellstedt according to current GMP guidelines. Besides deriving crude material from the traditional method of extracting raw vegetable materials, the company also embraces industrial biotechnological processes such as fermentation, using non-genetically modified organisms.